外周T细胞淋巴瘤PPT精品医学课件.pptVIP

RegimenStatus(n)ResponseToxicityAlemtuzumabalone(pilotstudy)[1]Relapsed(14)StudyclosedearlyORR:36%CMVreactivation:43%TRM:36%Alemtuzumab+CHOP[2]Primary(20)55%stageI/IIStudyclosedearlyCR:65%1-yrEFS:43%Grade4neutropenia:90%Febrileneutropenia:55%CMVreactivation:25%TRM:10%Alemtuzumab+CHOP[3]Primary(24)CR:71%2-yrFFS:48%2-yrOS:53%Severeneutropenia:34%CMVreactivation:9%Infection:aspergillus,sepsis,

JCvirusreact,pneumoniaAlemtuzumab+FCD(fludarabine,cyclophosphamide,doxorubicin)[4]Primary(27)Rel/refr(11)Studyclosed